Skip to content

Clinical observation of acupoint application in the treatment of diarrhea-type irritable bowel syndrome

A pilot study on the application of acupoint application technique in the treatment of diarrhea-type irritable bowel syndrome (liver stagnation and spleen deficiency) in primary hospitals

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006666
Enrollment
Unknown
Registered
2022-09-27
Start date
2022-09-27
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome

Interventions

2:Acupoint sticking

Sponsors

Tianjin Public Security Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Between the ages of 18 and 75, male and female; It met the diagnostic criteria of Rome ? diarrheal IBS subtype; It meets the diagnosis standard of the syndrome of liver stagnation and spleen deficiency in traditional Chinese medicine; The baseline IBS-SSS score is not less than 75; Patients volunteered to participate in the study and signed informed consent.

Exclusion criteria

Exclusion criteria: Diarrhoea due to other clearly diagnosed diseases, such as peptic ulcer disease, inflammatory bowel disease, tumour, etc.; Patients with serious diseases of liver, kidney, nerve, cardiovascular, respiratory and other organs or systems; Allergic to the drugs used in the protocol; Women in pregnancy; Mental illness, intellectual disability, education level and other reasons can not be surveyed; Those who have received drugs that may affect the judgment of curative effect in the past week, such as antispasmodic drugs, antidiarrhoetics, probiotics, antibiotics, anti-depressant and anxiety drugs, etc.; Patients with severe skin diseases, skin damage or poor glycemic control in the application area; Patients who are enrolled in another clinical trial or have completed another clinical trial for less than 3 months. Those who satisfy one or more of the above requirements will be excluded.

Design outcomes

Primary

MeasureTime frame
The Irritable bowel Syndrome Severity Score Scale;

Secondary

MeasureTime frame
Hamilton Depression Scale;The Irritable Bowel Syndrome Quality of Life;Hamilton Anxiety Scale;TCM syndrome score scale;Bristol Fecal Trait Scale;

Countries

China

Contacts

Public ContactYan Li
liyan66950@sina.com13612066950

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026